Monoclonal antibodies against PD-1 (nivolumab, pembrolizumab) and PD-L1 (atezolizumab, durvalumab, avelumab) have demonstrated durable responses and survival benefits, particularly in tumors with high PD-L1 expression, high tumor mutational burden (TMB), or microsatellite instability (MSI) [85]. This evidence concerns the gene CD274 and neoplasm.